Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Sclerosol

×

Overview

What is Sclerosol?

Sclerosol Intrapleural Aerosol (sterile talc powder 4 g) is a sclerosing agent for intrapleural administration supplied as a single-use, pressurized spray canister with two delivery nozzles of 15 cm and 25 cm in length. Each canister contains 4 g of talc, either white or off-white to light grey, asbestos-free, and brucite-free grade of talc of controlled granulometry. The composition of the talc is ≥ 95% talc as hydrated magnesium silicate. The empirical formula is MgSiO(OH) with molecular weight of 379.3. Associated naturally occurring minerals include chlorite (hydrated aluminum and magnesium silicate), dolomite (calcium and magnesium carbonite), calcite (calcium carbonate) and quartz. Talc is practically insoluble in water, and in dilute solutions of acids and alkali hydroxides. The canister and delivery nozzles have been sterilized by gamma irradiation. The aerosol propellant contained in Sclerosol® Intrapleural Aerosol is 1,1,1,2-Tetrafluoroethane (HFA-134a) with 25 g present per canister. The canister delivers 1.2 g of talc per second through the valve and the product contains no other excipients.



What does Sclerosol look like?



What are the available doses of Sclerosol?

Sorry No records found.

What should I talk to my health care provider before I take Sclerosol?

Sorry No records found

How should I use Sclerosol?

Sclerosol® Intrapleural Aerosol, administered by aerosol during thoracoscopy or open thoracotomy, is indicated to prevent recurrence of malignant pleural effusions in symptomatic patients.

Sclerosol® Intrapleural Aerosol (sterile talc powder) is administered after adequate drainage of the effusion. It has been suggested that success of the pleurodesis is related to the completeness of the drainage of the pleural fluid, as well as full reexpansion of the lung, both of which will promote symphysis of the pleural surfaces.

The usual dosage of Sclerosol® Intrapleural Aerosol (sterile talc powder) is a single 4-8 g dose delivered intrapleurally from the spray canister (1-2 cans), which delivers talc at a rate of 1.2 g per second.


What interacts with Sclerosol?

Sorry No Records found


What are the warnings of Sclerosol?

Sorry No Records found


What are the precautions of Sclerosol?

Sorry No Records found


What are the side effects of Sclerosol?

Sorry No records found


What should I look out for while using Sclerosol?

None known.

None.


What might happen if I take too much Sclerosol?

Overdosages have not been reported. See


How should I store and handle Sclerosol?

STORAGE:DISTRIBUTED BY: Bryan Corporation, Woburn MA 01801October 2012 STORAGE:DISTRIBUTED BY: Bryan Corporation, Woburn MA 01801October 2012 STORAGE:DISTRIBUTED BY: Bryan Corporation, Woburn MA 01801October 2012 Nifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXXNifedipine Extended-Release Tablets, USP are supplied as 30 mg and 60 mg round, biconvex, film-coated tablets which are 11 mm in diameter and 6 mm in height.  The different strengths can be identified as follows:Nifedipine extended-release tablets, USP are supplied in:The tablets should be protected from light and moisture and stored at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant containers.Manufactured for:Par Pharmaceutical Companies Inc.Spring Valley, NY 10977 U.S.A.Issued: 09/2012OS677-01-47-01XX-XXXX


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
None known.

None.

Drug Interactions:

Talc administration has been described in more than 1500 patients reported in the medical literature. Patients with malignant pleural effusions were treated with talc via poudrage or slurry. In general, with respect to reported adverse experiences, it is difficult to distinguish the effects of talc from the effects of the procedure(s) associated with its administration. The most reported common adverse experiences were fever and pain. Almost all of the cases of fever, and over half of the cases of pain, were in patients who received diagnostic biopsies at the time of talc administration.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).